Filtros de búsqueda

Lista de obras de

"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia

artículo científico publicado en 2010

"To switch or not to switch: that is the question"-more than 10% of ratio @ 3 months: how to treat chronic myeloid leukemia patients with this response?

artículo científico publicado en 2013

5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials

artículo científico publicado en 2012

A Multicenter Real-Life Study On Anticoagulant Treatment With Direct Oral Anticoagulants In Patients With Ph Negative Myeloproliferative Neoplasms

artículo científico publicado en 2020

A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.

artículo científico publicado en 2017

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

artículo científico publicado en 2020

A journey through infectious risk associated with ruxolitinib

scientific article published on 29 August 2019

A novel point mutation within the juxtamembrane domain of the flt3 gene in acute myeloid leukemia.

artículo científico publicado en 2010

AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation

artículo científico publicado en 2002

ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia?

artículo científico

Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients

artículo científico publicado en 2013

Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease

artículo científico publicado en 2008

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

artículo científico publicado en 2006

Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients

artículo científico publicado en 2011

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

artículo científico publicado en 2015

Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

artículo científico publicado en 2012

Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia

artículo científico publicado en 2016

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms

artículo científico publicado en 2015

Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response

artículo científico publicado en 2012

Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib

artículo científico publicado en 2013

Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment

artículo científico publicado en 2014

Are chronic myeloid leukemia patients ready to stop long-term treatment?

artículo científico publicado en 2017

Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?

artículo científico publicado en 2009

Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease

artículo científico

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart

scientific article published on 17 April 2019

Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation

artículo científico publicado en 2013

Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization

artículo científico publicado en 2012

Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy

artículo científico

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

artículo científico publicado en 2017

Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors

artículo científico publicado en 2017

Bosutinib for Chronic Myeloid Leukemia

artículo científico publicado en 2015

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey

artículo científico publicado en 2020

Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development?

artículo científico publicado en 2005

Can we safely discontinue imatinib? Searching for new endpoints in CML: a standardized definition of "cure".

artículo científico publicado en 2012

Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience

artículo científico publicado en 2007

Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.

artículo científico publicado en 2018

Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC).

artículo científico publicado en 2015

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion

artículo científico publicado en 2010

Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.

artículo científico publicado en 2018

Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias

artículo científico publicado en 2015

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

artículo científico publicado en 2011

Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase

artículo científico publicado en 2015

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

artículo científico

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

scientific article published on 18 June 2020

Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far?

artículo científico publicado en 2012

Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin

artículo científico publicado en 2008

Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation.

artículo científico publicado en 2005

Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy.

artículo científico publicado en 2004

Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution

artículo científico publicado en 2004

Clofarabine-Based Regimen as Useful Bridge Therapy for Allogeneic Transplantation in Myeloid Blast Crisis of Philadelphia-Positive Chronic Myeloid Leukemia Resistant to Imatinib and Dasatinib ⬇️

artículo científico publicado el 11 de octubre de 2010

Cocaine abuse may influence the response to imatinib in CML patients

artículo científico publicado en 2007

Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.

artículo científico publicado en 2009

Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia

artículo científico publicado en 2018

Comparison of JAK2(V617F) -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology

artículo científico publicado en 2017

Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia

artículo científico publicado en 2012

Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy

artículo científico publicado en 2010

Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront.

artículo científico publicado en 2015

Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.

artículo científico publicado en 2018

Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.

artículo científico

Current standard treatment of adult acute promyelocytic leukaemia

artículo científico publicado en 2015

Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib

artículo científico

Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen

artículo científico publicado en 2002

Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose

artículo científico publicado en 2010

Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life

artículo científico publicado en 2010

Dasatinib first-line: Multicentric Italian experience outside clinical trials

artículo científico publicado en 2015

Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations

artículo científico publicado en 2009

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

scientific article published on 25 June 2011

Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance

artículo científico publicado en 2009

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients

artículo científico publicado en 2010

Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results

artículo científico publicado en 2009

Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.

artículo científico publicado en 2015

Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.

artículo científico publicado en 2012

Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response

artículo científico publicado en 2010

Diabetes insipidus as first manifestation of acute myeloid leukaemia with EVI-1-positive, 3q21q26 syndrome and T cell-line antigen expression: what is the EVI-1 gene role?

artículo científico publicado en 2002

Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update

artículo científico publicado en 2017

Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia

artículo científico publicado en 2008

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a lar

artículo científico publicado en 2018

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

artículo científico publicado en 2018

Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome

scientific article published on 05 August 2019

Direct Oral Anticoagulants In Patients With Hematologic Malignancies

artículo científico publicado en 2020

Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response

artículo científico publicado en 2015

Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia

artículo científico

Do the smoking intensity and duration, the years since quitting, the methodological quality and the year of publication of the studies affect the results of the meta-analysis on cigarette smoking and Acute Myeloid Leukemia (AML) in adults?

artículo científico publicado en 2016

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

scholarly article by Francesca Palandri et al published November 2018 in Leukemia Research

Early and late complications related to central venous catheters in hematological malignancies: a retrospective analysis of 1102 patients

artículo científico

Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count

artículo científico publicado en 2003

Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation

artículo científico publicado en 2009

Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.

artículo científico publicado en 2007

Early molecular response in chronic myeloid leukemia and halving time: Latest evidences

artículo científico publicado en 2016

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

artículo científico publicado en 2013

Efficacy and safety of deferasirox in myelodysplastic syndromes

artículo científico publicado en 2013

Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis

scientific article published on 14 June 2019

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study

artículo científico publicado en 2017

Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase

artículo científico publicado en 2016

Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia

artículo científico publicado en 2011

Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment

artículo científico publicado en 2005

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.

artículo científico publicado en 2018

Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes

artículo científico publicado en 2010

Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.

artículo científico publicado en 2010

Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes

artículo científico publicado en 2011

Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy

artículo científico publicado en 2012

Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission

artículo científico publicado en 2002

Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib

artículo científico publicado en 2004

FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis

artículo científico publicado en 2013

FLT3-ITD in acute promyelocytic leukemia: clinical distinct profile but still controversial prognosis.

artículo científico publicado en 2015

Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes

artículo científico publicado en 2012

Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib

scientific article published on 29 June 2020

Firstline treatment for chronic phase chronic myeloid leukemia patients should be based on a holistic approach

artículo científico publicado en 2014

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome

artículo científico publicado en 2008

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

artículo científico publicado en 2010

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

artículo científico publicado en 2016

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

article by Gabriele Gugliotta et al published 26 May 2011 in Blood

Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia

artículo científico publicado en 2004

Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy ⬇️

artículo científico publicado el 11 de diciembre de 2010

Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome

artículo científico publicado en 2013

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

artículo científico publicado en 2011

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

artículo científico publicado en 2018

Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy

scientific article published on 02 September 2019

Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?

artículo científico publicado en 2016

Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience

artículo científico publicado en 2009

How can we improve the outcome of acute promyelocytic leukaemia patients relapsed after first-line arsenic trioxide? Definitely with an autologous stem cell transplant after second molecular remission

artículo científico publicado en 2020

How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety

artículo científico publicado en 2016

How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)

artículo científico publicado en 2020

How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes

artículo científico publicado en 2016

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey

artículo científico publicado en 2020

How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages

artículo científico

How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review

artículo científico publicado en 2014

Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment.

artículo científico publicado en 2018

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice

scientific article published on 05 June 2019

Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion

artículo científico publicado en 2016

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

artículo científico publicado en 2016

Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up

artículo científico publicado en 2010

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

artículo científico publicado en 2013

Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?

artículo científico publicado en 2010

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib

scientific article published on 07 June 2019

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

artículo científico publicado en 2012

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

scientific article published on 04 December 2018

Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia

artículo científico publicado en 2015

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

artículo científico publicado en 2016

Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?

artículo científico publicado en 2015

Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib

artículo científico publicado en 2014

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

artículo científico publicado en 2017

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

artículo científico publicado en 2012

Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia

artículo científico publicado en 2016

Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results

artículo científico publicado en 2009

Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols

artículo científico publicado en 2012

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia

International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.

artículo científico publicado en 2013

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.

artículo científico publicado en 2018

Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy.

artículo científico publicado en 2015

Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.

artículo científico publicado en 2011

Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.

artículo científico publicado en 2011

Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose

artículo científico publicado en 2008

Isolated myeloid sarcoma without bone marrow involvement

artículo científico publicado en 2012

Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative

artículo científico publicado en 2019

Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?

artículo científico publicado en 2014

Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy

artículo científico publicado en 2013

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

artículo científico publicado en 2019

Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project

artículo científico publicado en 2018

Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia

artículo científico publicado en 2008

Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era

scientific article published on 01 February 2014

Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.

artículo científico publicado en 2017

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

artículo científico publicado en 2015

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

artículo científico publicado en 2008

Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase

artículo científico publicado en 2011

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

artículo científico publicado en 2020

Low-Dose Ponatinib Is A Good Option In Chronic Myeloid Leukemia Patients Intolerant To Previous Tkis

scientific article published on 17 June 2020

Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option

artículo científico publicado en 2018

MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine

artículo científico publicado en 2012

Maintenance therapy in AML: The past, the present and the future

scientific article published on 11 September 2019

Management of acute promyelocytic leukemia in the elderly

artículo científico publicado en 2013

Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab

artículo científico publicado en 2020

Management of the 2009 A/H1N1 influenza pandemic in patients with hematologic diseases: a prospective experience at an Italian center

artículo científico publicado en 2011

Management options for refractory chronic myeloid leukemia: considerations for the elderly

artículo científico publicado en 2013

Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment

artículo científico publicado en 2009

Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia

artículo científico publicado en 2015

Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)

artículo científico publicado en 2021

Myelodysplastic syndromes in patients under 50 years old: a single institution experience.

artículo científico publicado en 2005

NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia ⬇️

artículo científico publicado el 1 de noviembre de 2010

Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells

artículo científico publicado en 2014

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

artículo científico

Nilotinib and dasatinib—new 'magic bullets' for CML? ⬇️

artículo científico publicado el 1 de octubre de 2010

Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy

artículo científico publicado en 2007

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

artículo científico publicado en 2009

Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences.

artículo científico publicado en 2011

Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.

artículo científico publicado en 2009

Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index

artículo científico publicado en 2012

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia

artículo científico publicado en 2010

Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy.

artículo científico publicado en 2018

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice

scientific article published on 28 February 2019

Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors

artículo científico publicado en 2013

Ocular side effects in chronic myeloid leukemia patients treated with imatinib

artículo científico publicado en 2007

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

artículo científico publicado en 2012

Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes

artículo científico publicado en 2017

Patient-reported outcomes in acute leukemia: a roadmap for future research

artículo científico publicado en 2014

Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis

artículo científico publicado en 2016

Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios

artículo científico publicado en 2021

Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients

artículo científico publicado en 2017

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

artículo científico publicado en 2017

Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib

artículo científico publicado en 2005

Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development

artículo científico publicado en 2010

Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.

artículo científico publicado en 2018

Ponatinib: A Review of Efficacy and Safety

artículo científico publicado en 2017

Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience

artículo científico publicado en 2011

Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience

artículo científico publicado en 2020

Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes

artículo científico publicado en 2014

Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors

artículo científico publicado en 2013

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib

artículo científico publicado en 2017

Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience

artículo científico publicado en 2012

Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study

artículo científico publicado en 2015

Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?

artículo científico publicado en 2012

Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid.

artículo científico publicado en 2006

Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline

artículo científico publicado en 2016

Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies

artículo científico publicado en 2016

Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment

scientific article published on 23 January 2020

Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians

artículo científico publicado en 2011

RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA

scientific article published on 09 April 2020

Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.

artículo científico publicado en 2016

Recurrent Sweet's syndrome in acute myeloid leukemia successfully treated with amphotericin B.

artículo científico publicado en 2004

Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance

artículo científico publicado en 2010

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib ⬇️

artículo científico publicado el 1 de octubre de 2008

Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients

artículo científico publicado en 2010

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

artículo científico publicado en 2018

Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem

scientific article published on March 2009

Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia.

artículo científico publicado en 2004

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

artículo científico publicado en 2009

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia

artículo científico publicado en 2013

Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine

artículo científico publicado en 2012

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

artículo científico publicado en 2016

Role of gamma-glutamyl cysteine synthetase (gamma-GCS) gene expression as marker of drug sensitivity in acute myeloid leukemias

artículo científico publicado en 2005

Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia

artículo científico publicado en 2017

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

artículo científico publicado en 2016

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

artículo científico publicado en 2021

Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.

artículo científico publicado en 2016

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients

artículo científico publicado en 2018

Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months

artículo científico publicado en 2010

Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly

Second line small molecule therapy options for treating chronic myeloid leukemia

artículo científico publicado en 2016

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

artículo científico publicado en 2020

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs

artículo científico

Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.

artículo científico publicado en 2009

Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML).

artículo científico publicado en 2014

Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?

artículo científico publicado en 2009

Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study

artículo científico publicado en 2020

Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients

artículo científico publicado en 2016

Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.

artículo científico publicado en 2015

Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challenges

artículo científico

Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide ⬇️

artículo científico publicado el 12 de enero de 2011

Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients

artículo científico publicado en 2020

Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms

article

Systematic review of dasatinib in chronic myeloid leukemia

artículo científico publicado en 2013

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

artículo científico publicado en 2017

The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials

artículo científico publicado en 2017

The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose

artículo científico publicado en 2011

The degree of anemia has an impact on survival in myelodysplastic syndrome patients classified with WPSS.

artículo científico publicado en 2011

The importance of molecular monitoring in acute promyelocytic leukaemia

artículo científico publicado en 2003

The limit for chronic myeloid leukemia relapse after allogeneic hematopoietic stem cell transplant moves ever forward: when can you safely talk about healing?

artículo científico publicado en 2012

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

artículo científico publicado en 2009

The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism

artículo científico publicado en 2009

The pros and cons of new prognostic eutos score for chronic myeloid leukemia patients

artículo científico publicado en 2013

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

artículo científico publicado en 2010

The role of comorbidities in chronic myeloid leukemia

artículo científico publicado en 2013

The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era ⬇️

artículo científico publicado el 4 de agosto de 2010

Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem

artículo científico publicado en 2002

Thrombo-hemorrhagic deaths in acute promyelocytic leukemia

artículo científico

Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life

artículo científico publicado en 2017

Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice

scientific article published on 12 December 2019

Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian Population.

artículo científico publicado en 2019

Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response

artículo científico publicado en 2009

Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.

artículo científico publicado en 2011

Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice

scientific article published on 18 November 2020

Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data

artículo científico publicado en 2012

Unusual association of paroxysmal cold hemoglobinuria as the first sign of disease in myelodysplastic patient

artículo científico publicado en 2009

Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations

artículo científico

Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes

artículo científico publicado en 2005

Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia

artículo científico publicado en 2020

Validation of a new proposed relapse risk score (CBC-score) for acute promyelocytic leukaemia

artículo científico publicado en 2013

Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group

artículo científico publicado en 2012

Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning

scientific article published on 18 June 2020

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda